ArticleOncotarget2017
PAQR3 suppresses the proliferation, migration and tumorigenicity of human prostate cancer cells.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- The role of PAQR3 in cancer progression - Molecular regulation, signaling pathways, and clinical implications: A review.Biomolecules & biomedicine · 2026Review
- Downregulation of PAQR3 expression predicts poor prognosis of patients with pan-cancer: a meta-analysis.Frontiers in oncology · 2025Review
- The Emerging Roles and Mechanisms of PAQR3 in Human Cancer: Pathophysiology and Therapeutic Implications.International journal of general medicine · 2023Review
- Golgi Complex: A Signaling Hub in Cancer.Cells · 2022Review
- CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis.Communications biology · 2021Article
- PAQR3 suppresses the growth of non-small cell lung cancer cells via modulation of EGFR-mediated autophagy.Autophagy · 2020Article
- PAQR3 protects against oxygen-glucose deprivation/reperfusion-induced injury through the ERK signaling pathway in N2A cells.Journal of molecular histology · 2020Article
- Characterization of the Golgi scaffold protein PAQR3, and its role in tumor suppression and metabolic pathway compartmentalization.Cancer management and research · 2020Review
- PAQR3 inhibits proliferation via suppressing PI3K/AKT signaling pathway in non-small cell lung cancer.Archives of medical science : AMS · 2018Article
- Suppressor PAQR3 associated with the clinical significance and prognosis in esophageal squamous cell carcinoma.Oncology letters · 2018Article
- miR-221-5p enhances cell proliferation and metastasis through post-transcriptional regulation of SOCS1 in human prostate cancer.BMC urology · 2018Article
- Progestin and AdipoQ Receptor 3 Upregulates Fibronectin and Intercellular Adhesion Molecule-1 in Glomerular Mesangial CellsFrontiers in endocrinology · 2018Article
- PAQR3 Inhibits the Proliferation and Tumorigenesis in Esophageal Cancer Cells.Oncology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As a newly discovered tumor suppressor, the potential function of PAQR3 in human prostate cancer has not been demonstrated. In this study, we report that PAQR3 is able to inhibit the growth and migration of human prostate cancer cells both
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.